Table 1 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
收藏数据链接：
官方服务：
资源简介：
Summary table of completed and ongoing sponsor-initiated phase I and II clinical trials with tepotinib in patients with cancer.
创建时间：
2023-07-05
